|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | First series (n=87) | | | |  | Second series (n=35) | | | | Total (n=122) | |
| Genes | Repeat | Percentage of tumours  with mutations | | Percentage of mutated  samples with mutations  in all malignant cells | |  | Percentage of tumours  with mutations | | Percentage of mutated  samples with mutations  in all malignant cells | | Percentage of tumours  with mutations | Percentage of mutated  samples with mutations  in all malignant cells |
| *ACVR2* | (A)8 | 90.6 % | (77/85) | 34.2 % | (26/76) |  | 97.1 % | (33/34) | 37.5 % | (12/32) | 92 % | 35 % |
| *TAF1B* | (A)11 | 84.9 % | (73/86) | 1.4 % | (1/72) |  | 82.4 % | (28/34) | 0.0 % | (0/27) | 84 % | 1 % |
| *ASTE1* | (A)11 | 76.6 % | (63/82) | 34.9 % | (22/63) |  | 93.8 % | (30/32) | 26.7 % | (8/30) | 82 % | 32 % |
| *TGFBR2* | (A)10 | 78.8 % | (67/85) | 36.4 % | (24/66) |  | 78.1 % | (25/32) | 12.0 % | (3/25) | 79 % | 30 % |
| *SEC63* | (A)9 and (A)10 | 68.7 % | (57/83) | 7.1 % | (4/56) |  | 78.8 % | (26/33) | 0.0 % | (0/26) | 72 % | 5 % |
| *CASP5* | (A)10 | 67.9 % | (57/84) | 8.9 % | (5/56) |  | 68.8 % | (22/32) | 9.5 % | (2/21) | 68 % | 9 % |
| *AIM2* | (A)10 | 56.3 % | (40/71) | 20.5 % | (8/39) |  | 92.9 % | (26/28) | 15.4 % | (4/26) | 67 % | 18 % |
| *MSH3* | (A)8 | 55.3 % | (47/85) | 10.9 % | (5/46) |  | 63.6 % | (21/33) | 0.0 % | (0/21) | 58 % | 7 % |
| *TCF7L2* | (A)9 | 44.3 % | (31/70) | 10.0 % | (3/30) |  | 41.4 % | (12/29) | 8.3 % | (1/12) | 43 % | 10 % |
| *HNF1A* | (A)8 | 41.9 % | (31/74) | 0.0 % | (0/30) |  | 44.8 % | (13/29) | 0.0 % | (0/13) | 43 % | 0 % |
| *OGT* | (A)10 | 38.3 % | (31/81) | 6.7 % | (2/30) |  | 45.5 % | (15/33) | 6.7 % | (1/15) | 40 % | 7 % |
| *MBD4* | (A)10 | 39.3 % | (33/84) | 6.2 % | (2/32) |  | 37.9 % | (11/29) | 18.2 % | (2/11) | 39 % | 9 % |
| *BAX* | (G)8 | 31.0 % | (22/71) | 4.5 % | (1/22) |  | 54.8 % | (17/31) | 17.6 % | (3/17) | 38 % | 10 % |
| *PTEN* | (A)6 exon 8  exon 7 | 41.5 %  15.0 % | (34/82)  (13/87) | 3.1 %  9.1 % | (1/32)  (1/11) |  | 25.0 %  33.3 % | (8/32)  (11/33) | 12.5 %  8.3 % | (1/8) (1/12) | 37 %  20 % | 5 %  9 % |
| *IGFR2* | (G)8 | 33.7 % | (27/80) | 7.4 % | (2/27) |  | 41.2 % | (14/34) | 7.1 % | (1/14) | 36 % | 7 % |
| *RAD50* | (A)9 | 29.1 % | (23/79) | 9.1 % | (2/22) |  | 51.6 % | (16/31) | 6.3 % | (1/16) | 35 % | 8 % |
| *PRDM2* | (A)8  (A)9 | 34.3 %  16.7 % | (23/67)  (13/78) | 4.5 %  0.0 % | (1/22)  (0/12) |  | 34.4 %  39.3 % | (11/32)  (11/28) | 0.0 %  9.1 % | (0/10)  (1/11) | 34 %  23 % | 3 %  4 % |
| *MSH6* | (C)8 | 25.3 % | (21/83) | 0.0 % | (0/21) |  | 28.1 % | (9/32) | 0.0 % | (0/8) | 26 % | 0 % |
| *APC* | (A)7 | 24.0 % | (18/75) | 5.9 % | (1/17) |  | 10.3 % | (3/29) | 33.3 % | (1/3) | 20 % | 10 % |